PRIMARY MYELOFIBROSIS: UPDATE ON PATHOGENESIS, DIAGNOSIS AND MANAGEMENT

Yıl 2014, Cilt: 77 Sayı: 4, 67 - 77, 13.03.2015

İpek Yönal , Fatma Sargın

https://doi.org/10.18017/iuitfd.13056441.2015.77/4.67-77

Öz

Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm (MPN) characterized by anemia, teardropshaped red cells in blood, leukoerythroblastosis, bone marrow fibrosis, osteosclerosis and extramedullary hematopoiesis. Approximately 50% of PMF patients harbor JAK2V617F mutation and MPL mutations are present in a further 10%. Bone marrow examination reveals a hypercellular bone marrow with atypical megakaryocytes and slight marrow fibrosis in cellular phase of PMF. Diagnosis requires the exclusion of other MPN. Most patients are diagnosed in the fibrotic phase of PMF, when fibrosis is typically extensive with reticulin fibers and often subsequently accompanied by collagen fibrosis. Overall median survival is approximately 5 years. Death is mainly due to leukemic transformation, accounting for 20% of PMF patients. Others succumb to consequences of cytopenias such as infection or bleeding or to comorbid conditions including cardiovascular events. A number of prognostic scoring systems have been developed for PMF (eg. IPSS, DIPPS, DIPSS Plus). Analysis of a total of 879 patients included in a European and Mayo Clinic cohort showed that ASXL1, SRSF2 and EZH2 mutations independently predicted shortened survival. Leukemia-free survival (LFS) was negatively affected by IDH1/2, SRSF2, and ASXL1 mutations. Profiling for ASXL1, EZH2, SRSF2 and IDH mutations may identify PMF patients at risk for leukemic transformation or death. Currently, these molecular markers are mainly of research interest. Allogeneic hematopoietic stem cell transplantation (AHSCT) is the only curative treatment modality in PMF, yet it is associated with high treatment-related mortality. All other treatment modalities are palliative and show differences in efficacy and toxicity. There are few randomized trials comparing these modalities. Thus, it is not possible to make strong recommendations for selecting one treatment over another. This review aims to highlight the pathogenesis, diagnosis and current management in PMF

Anahtar Kelimeler

JAK2V617F mutation, MPL mutations, Myeloproliferative neoplasms, Primary myelofibrosis

PRİMER MİYELOFİBROZİS: PATOGENEZ, TEŞHİS VE TEDAVİDE GÜNCEL BİLGİLER

Öz

Primer miyelofibrozis (PMF), anemi, periferik kan yaymasında ‘tear drop’ şeklinde eritrositler, lökoeritroblastozis, kemik iliği fibrozisi, osteosklerozis ve ekstramedüller hematopoez ile karakterize miyeloproliferatif neoplazilerden (MPN) biridir. JAK2V617F mutasyonu PMF olgularının yaklaşık %50’sinde ve MPL mutasyonları %10’unda görülmektedir. PMF’in hücresel fazında kemik iliği biyopsisi atipik megakaryositler ve belirgin olmayan kemik iliği fibrozisi ile birlikte hiperselüler kemik iliğini ortaya çıkarır. PMF tanısı için diğer MPN’lerin dışlanması gerekmektedir. Birçok hasta PMF’in fibrotik fazında tanı alır. Bu fazdaki hastalarda fibrozis, tipik olarak yoğun retikülin lif artışı şeklinde ortaya çıkmakla beraber sonrasında sıklıkla kollagen fibrozisi gözlenir. Ortalama yaşam süresi yaklaşık 5 yıldır. PMF’in yaklaşık %20’sinde ortaya çıkan lösemik transformasyon, ölümün başlıca nedenidir. Diğer ölüm nedenleri arasında kardiyovasküler hastalıklar gibi komorbid hastalıklar yanında sitopeniye bağlı ortaya çıkan enfeksiyonlar ve kanama vardır. PMF için birkaç prognostik skorlama sistemi geliştirilmiştir (örneğin IPSS, DIPSS, DIPSS Plus). PMF’deki somatik mutasyonların prognostik önemi araştırılmıştır. ASXL1, SRSF2 ve EZH2 mutasyonlarının kısa yaşam süresi ile ilişkili bağımsız faktörler olduğu ve IDH1, IDH2, SRSF2 ve ASXL1 mutasyonlarının lösemi ilişkisiz sağkalımı (LFS) kısalttığı bildirilmiştir. Sonuç olarak PMF’de ASXL1, EZH2, SRSF2 ve IDH mutasyonlarının lösemik transformasyon veya ölüm riskini belirlemede yararlı olabileceği söylenebilir. Günümüzde bu moleküler belirteçler yoğun araştırma konusudur. PMF’de tek küratif tedavi yöntemi allogeneik hematopoetik kök hücre nakli (AHKHN) olmasına rağmen tedavi ile ilişkili mortalite oranı yüksektir. AHKHN dışındaki diğer tedavi şekilleri palyatif olup farklı etkinlik ve toksisiteye sahiptir. PMF’de tedavi yöntemlerini karşılaştıran az sayıda çalışma olduğundan, aralarından seçim yapılarak önerilmesi mümkün değildir. Bu derlemenin amacı, PMF tanılı olgularda patogenez, tanı yöntemleri ve güncel tedaviyi özetlemektir.

Anahtar Kelimeler

JAK2V617F mutasyonu, Miyeloproliferatif neoplaziler, MPL mutasyonları, Primer miyelofibrozis

Kaynakça

• Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3):358-67.
• Barosi G. Myelofibrosis with myeloid metaplasia. Hematol Oncol Clin North Am. 2003;17(5):1211-26.
• Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project. Acquired mutation of the myeloproliferative 2005;365(9464):1054-61. JAK2 disorders. Lancet.
• Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb;25(2):301-4. Epub 2010 Nov 5.
• Bench AJ, Nacheva EP, Champion KM, Green AR. Molecular myeloproliferative Haematol. 1998;11(4):819-48. cytogenetics Baillieres Clin Bird GW, Wingham J, Richardson SG.
• Myelofibrosis, autoimmune haemolytic anaemia and Tn-polyagglutinability. 1985;18(2):99-103. Haematologia (Budap).
• Buhr T, Büsche G, Choritz H, Länger F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol. 2003;119(1):152-8.
• Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia. 1988;2(10):658-60.
• Cappio FC, Vigliani R, Novarino A, Camussi G, Campana D, Gavosto F. Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol. 1981;49(1):17-21.
• Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, Hanson C, Pardanani A, Tefferi A. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82-8..
• Carlo-Stella C, Cazzola M, Gasner A, Barosi G, Dezza L, Meloni F, Pedrazzoli P, Hoelzer D, Ascari E. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU- Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood. 1987;70(4):1014-9.
• Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MA. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood. 1981;57(4):781-7.
• Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004;127(4):399-403. Review.
• Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E. Myelofibrosis with myeloid metaplasia in young individuals: factors and identification of risk groups. Br J Haematol. 1998;102(3):684-90. prognostic
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895–2901.
• Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007;13(6):377-83.
• Cox MC, Panetta P, Venditti A, Abruzzese E, Del Poeta G, Cantonetti M, Amadori S. New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. Leuk Res. 2001;25(4):349-51.
• Demory JL, Dupriez B, Fenaux P, Laï JL, Beuscart R, Jouet JP, Deminatti M, Bauters F. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood. 1988;72(3):855-9.
• Gaidano G, Guerrasio A, Serra A, Carozzi F, Cambrin GR, Petroni D, Saglio G. Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative 1993;7(7):946-53. disorders. Leukemia.
• Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS plus: a refined Dynamic International Prognostic myelofibrosis information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-7.
• Giraudier S, Chagraoui H, Komura E, Barnache S, Blanchet B, LeCouedic JP, Smith DF, Larbret F, Taksin AL, Moreau-Gachelin F, Casadevall N, Tulliez M, Hulin A, Debili N, Vainchenker W. Overexpression myelofibrosis independence of megakaryocyte progenitors. Blood. 2002;100(8):2932-40. FKBP51 in growth regulates the factor
• Hernández JM, San Miguel JF, González M, Orfao A, Cañizo MC, Bascones C, Hernández J, López Borrasca A. Development of acute leukaemia after idiopathic 1992;45(5):427-30. J Clin Pathol.
• Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Risk factors for leukemic transformation myelofibrosis. Cancer. 2008;112(12):2726-32. patients with primary
• Huang J, Tefferi A. Erythropoiesis stimulating agents transfusion-dependent myelofibrosis regardless of serum erythropoietin level. Eur J Haematol. 2009 Aug;83(2):154-5. doi: 1111/j.1600-0609.2009.01266.x. Epub 2009 Apr therapeutic patients in with primary
• James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8.
• Jones LC, Tefferi A, Vuong PT, Desmond JC, Hofmann WK, Koeffler HP. Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells. 2005;23(5):631-7.
• Jowitt SN, Burke DK, Leggat HM, Lewis PS, Cryer RJ. Pleural effusion secondary to extramedullary haemopoiesis myelofibrosis responding to pleurodesis and hydroxyurea. Clin Lab Haematol. 1997;19(4):283-5.
• Kahn A, Bernard JF, Cottreau D, Marie J, Boivin P. Gd(--) Abrami: a deficient G-6PD variant with hemizygous expression in blood cells of a woman with 1975;30(1):41-6. Humangenetik.
• Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90. of JAK2 in
• Kreft A, Weiss M, Wiese B, Choritz H, Buhr T, Büsche G, Georgii A. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses by using the RECPAM method. Ann Hematol. 2003;82(10):605-11.
• Kreipe H, Jaquet K, Felgner J, Radzun HJ, Parwaresch MR. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood. 1991;78(7):1814-7.
• Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120(20):4168-71.
• Ligumski M, Polliack A, Benbassat J. Myeloid metaplasia of the central nervous system in patients with metaplasia. Report of 3 cases and review of the literature. Am J Med Sci. 1978;275(1):99-103.
• Loewy G, Mathew A, Distenfeld A. Skin manifestation of agnogenic myeloid metaplasia. Am J Hematol. 1994;45(2):167-70.
• Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single- institution experience with 91 cases. Blood. 2005;105(3):973-7.
• Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361–370.
• Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, intrahepatic portosystemic shunt. Eur J Haematol. 2010;85(3):192-9. and transjugular
• Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-96.
• Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, D'Urzo C, Vannucchi AM, Barosi G, Barbui T. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446-55. positive chronic
• Rege-Cambrin G, Speleman F, Kerim S, Scaravaglio P, Carozzi F, Dal Cin P, Michaux JL, Offner F, Saglio G, Van den Berghe H. Extra translocation +der(1q9p) myeloproliferative 1991;5(12):1059-63. disorders. in Leukemia.
• Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98(1):96-102.
• Reilly JT, Wilson G, Barnett D, Watmore A, Potter A. Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis. Br J Haematol. 1994;88(3):575-81.
• Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Brianzoni MF, D'Amico S, Cinciripini A, Leoni P. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol. 1994;68(4):205-12.
• Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP- 701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia 2010;115(6):1131-6.. myelofibrosis. Blood.
• Taksin AL, Couedic JP, Dusanter-Fourt I, Massé A, Giraudier S, Katz A, Wendling F, Vainchenker W, Casadevall megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 1999;93(1):125-39. N. Autonomous
• Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(2):141-50.
• Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108(4):1158-64. Epub 2006 Apr
• Tefferi A, Elliot MA, Yoon SY, Li CY, Mesa RA, Call TG, Dispenzieri A. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood. 2001 Mar 15;97(6):1896.
• Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and 2008;22(4):756-61. survival. Leukemia.
• Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007;21(8):1827-8. Epub 2007 Apr 26.
• Tefferi A, Litzow MR, Pardanani A. Long-term outcome myelofibrosis. N Engl J Med. 2011;365(15):1455-7.
• Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001 Jun;113(3):763-71.
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point- of-care diagnostic algorithms. Leukemia. 2008; 22(1):14-22. 2008;22(11):2118-9. in: Leukemia.
• Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563-9. homas DA, Giles FJ, Albitar M, Cortes JE,
• Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006;106(9):1974-84.
• Tsukamoto N, Morita K, Maehara T, Okamoto K, Sakai H, Karasawa M, Naruse T, Omine M. Clonality in chronic myeloproliferative disorders defined demonstration involvement. Br J Haematol. 1994;86(2):253-8.
• Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117
• Wang JC, Chen C. P16 gene deletions and point mutations in patients with agnogenic myeloid metaplasia (AMM). Leuk Res. 1999;23(7):631-5.
• Yotsumoto M, Ishida F, Ito T, Ueno M, Kitano K, Idiopathic Kiyosawa refractory 2003;42(6):525-8. myelofibrosis with Med. ascites. Intern
• Zojer N, Meran JG, Vesely M, Grüner H, Ackermann J, Dellinger C, Zimmer-Roth I, Heinz R, Drach J, Ludwig H. Trisomy 13 is associated with poor prognosis in idiopathic myelofibrosis with myeloid metaplasia. Leuk Lymphoma. 1999;35(3- 4):415-21.